Labroots

Mastering Small Molecule Reversed-Phase Method Development

Join us for an expert-led webinar with Adham Ahmed as he delves into the intricacies of developing robust and reliable reversed-phase chromatography methods. This session will cover critical ...
Business Wire

PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Urgent ...

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies ...
Nasdaq

Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis due to NASH Did Not Meet its Primary Endpoint

Company remains on track to resubmit new drug application (NDA) for OCA in its lead indication of fibrosis due to NASH by year end based on its positive Phase 3 REGENERATE study MORRISTOWN, N.J., Sept ...
Baylor College of Medicine

Reverse Phase Protein Array Publications

Zhongcheng Shi, Michael Hoang Nguyen, Yuan Yao, Shixia Huang. High-Throughput Post-Translational Modification Analyses by Reverse Phase Protein Array. Protein Arrays: methods and applications. 2024 ...
Baylor College of Medicine

Reverse Phase Protein Array Core Services

Reverse phase protein array is a high-throughput technology that performs protein assays on thousands of samples simultaneously, including tissue and cell lysates, serum, plasma or other body fluids.
Nasdaq

PhaseBio Doses First Patients in Canada as Part of the REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of the Antiplatelet Effects of Ticagrelor

Cardiovascular disease remains a leading cause of mortality in both Canada and globally; the lack of reversal agents for patients taking antiplatelet therapies who require urgent surgery or experience ...